Impact of voglibose on the pharmacokinetics of dapagliflozin in japanese patients with type 2 diabetes

Diabetes Therapy

Volumn 4, Issue 1, 2013, Pages 41-49

  Imamura, Akira ^a   Kusunoki, Masahito ^b   Ueda, Shinya ^c   Hayashi, Nobuya ^c   Imai, Yasuhiko ^d  

^a Keiyu Hospital   (Japan)

^b KOBE INTERNATIONAL UNIVERSITY   (Japan)

^c ASTRAZENECA   (United Kingdom)

^d Shinjuku Island Tower   (Japan)

Author keywords

Dapagliflozin; drug drug interaction; Pharmacokinetics; Sodium glucose cotransporter 2 inhibitor; Type 2 diabetes; Voglibose

Indexed keywords

C PEPTIDE; DAPAGLIFLOZIN; GLIMEPIRIDE; GLUCOSE; GLUCURONOSYLTRANSFERASE 1A9; HEMOGLOBIN A1C; METFORMIN; PIOGLITAZONE; SITAGLIPTIN; SODIUM GLUCOSE COTRANSPORTER 2; VOGLIBOSE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BRONCHITIS; CLINICAL ARTICLE; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; FEMALE; GINGIVITIS; GLYCEMIC CONTROL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIMIT OF QUANTITATION; MALE; MAXIMUM PLASMA CONCENTRATION; MIDDLE AGED; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL PARESTHESIA; PERIPHERAL EDEMA; PLASMA CLEARANCE; POLLAKISURIA; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 84891871893     PISSN: 18696953     EISSN: 18696961     Source Type: Journal    
DOI: 10.1007/s13300-012-0016-5     Document Type: Article

References (28)

1. Danaei G, Finucane MM, Lu Y, et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet. 2011;378:31-40.
2. The Japan Diabetes Society. Introduction to the Japan Diabetes Society. http://www.jds.or.jp/e/about_jds/message.html. Accessed 25 Apr 2012.
3. Neville SE, Boye KS, Montgomery WS, Iwamoto K, Okamura M, Hayes RP. Diabetes in Japan: a review of disease burden and approaches to treatment. Diabetes Metab Res Rev. 2009;25:705-16.
4. Odaka H, Shino A, Ikeda H, Matsuo T. Antiobesity and antidiabetic actions of a new potent disaccharidase inhibitor in genetically obesediabetic mice, KKA(y). J Nutr Sci Vitaminol (Tokyo). 1992;38:27-37.
5. Fuder H, Kleist P, Birkel M, et al. The alphaglucosidase inhibitor voglibose (AO-128) does not change pharmacodynamics or pharmacokinetics of warfarin. Eur J Clin Pharmacol. 1997;53:153-7.
6. Goke B, Fuder H, Wieckhorst G, et al. Voglibose (AO-128) is an efficient alpha-glucosidase inhibitor and mobilizes the endogenous GLP-1 reserve. Digestion. 1995;56:493-501.
7. Horii S, Fukase H, Matsuo T, Kameda Y, Asano N, Matsui K. Synthesis and alpha-D-glucosidase inhibitory activity of N-substituted valiolamine derivatives as potential oral antidiabetic agents. J Med Chem. 1986;29:1038-46.
8. Chao EC, Henry RR. SGLT2 inhibition-a novel strategy for diabetes treatment. Nat Rev Drug Discov. 2010;9:551-9.
9. Meng W, Ellsworth BA, Nirschl AA, et al. Discovery of dapagliflozin: a potent, selective renal sodiumdependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. J Med Chem. 2008;51:1145-9.
10. Ferrannini E, Ramos SJ, Salsali A, Tang W, List JF. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebocontrolled, phase III trial. Diabetes Care. 2010;33:2217-24.
11. Henry R, Murray A, Marmolejo MH, Hennicken D, Ptaszynska A, List JF. Dapagliflozin, metformin-XR, or both together as initial therapy for T2DM [abstract]. Diabetes. 2011;60:A84. Abstract 307-OR.
12. Bailey CJ, Gross JL, Pieters A, Bastien A, List JF. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;375:2223-33.
13. Bailey CJ, Gross JL, Yadav M, Iqbal N, Mansfield TA, List JF. Long-term efficacy of dapagliflozin as addon to metformin (MET) in T2DM inadequately controlled with metformin alone [abstract]. Diabetes. 2011;60:A271. Abstract 988-P.
14. Jabbour S, Hardy E, Sugg J, Parikh S. Dapagliflozin as add-on therapy to sitagliptin with or without metformin: a randomized, double-blind, placebocontrolled study. Diabetes. 2012;61:A275. Abstract 1071-P.
15. Nauck MA, Del PS, Meier JJ, et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care. 2011;34:2015-22.
16. Rosenstock J, Vico M, Wei L, Salsali A, List JF. Effects of dapagliflozin, a sodium-glucose cotransporter-2 inhibitor, on hemoglobin A1c, body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy. Diabetes Care. 2012;35:1473-8.
17. Strojek K, Hruba V, Elze M, Langkilde A, Parikh S. Efficacy and safety of dapagliflozin in patients with type 2 diabetes mellitus and inadequate glycaemic control on glimepiride monotherapy [abstract]. Diabetologia. 2010;53:S347. Abstract 870.
18. Kageyama S, Nakamichi N, Sekino H, Nakano S. Comparison of the effects of acarbose and voglibose in healthy subjects. Clin Ther. 1997;19:720-9.
19. Salsali A, Hruba V, Ying L, et al. Reduction in postprandial glucose with dapagliflozin in type 2 diabetes [abstract]. Diabetes. 2011;60:A303. Abstract 1104-P.
20. Kasichayanula S, Chang M, Hasegawa M, et al. Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodium-glucose co-transporter type 2, in Japanese subjects without and with type 2 diabetes mellitus. Diabetes Obes Metab. 2011;13:357-65.
21. Komoroski B, Vachharajani N, Feng Y, Li L, Kornhauser D, Pfister M. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin Pharmacol Ther. 2009;85:513-9.
22. Komoroski B, Vachharajani N, Boulton D, et al. Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharmacol Ther. 2009;85:520-6.
23. Obermeier M, Yao M, Khanna A, et al. In vitro characterization and pharmacokinetics of dapagliflozin (BMS-512148), a potent sodiumglucose cotransporter type II inhibitor, in animals and humans. Drug Metab Dispos. 2010;38:405-14.
24. Kasichayanula S, Liu X, Shyu WC, et al. Lack of pharmacokinetic interaction between dapagliflozin, a novel SGLT2 inhibitor, and metformin, pioglitazone, glimepiride, or sitagliptin in healthy subjects. Diabetes Obes Metab. 2011;13:47-54.
25. Kasichayanula S, Chang M, Liu X, et al. Lack of pharmacokinetic interactions between dapagliflozin and simvastatin, valsartan, warfarin, or digoxin. Adv Ther. 2012;29:163-77.
26. Methods of Investigation for Drug Interactions. PMSB/ELD Notification, vol No 813. 2001.
27. Trovato A, Nuhlicek DN, Midtling JE. Drug-nutrient interactions. Am Fam Physician. 1991;44:1651-8.
28. Nakamura T, Takebe K, Kudoh K, et al. Effect of an alpha-glucosidase inhibitor on intestinal fermentation and faecal lipids in diabetic patients. J Int Med Res. 1993;21:257-67.